Baidu
map

J Am Heart Assoc:维生素D能改善老年人血压、动脉硬化和心脏功能吗

2017-11-28 何娜 环球医学

2017年10月,发表在《J Am Heart Assoc》的BEST-D(Biochemical Efficacy and Safety Trial of Vitamin D,维生素D的生化功效和安全性试验)试验,考察了补充维生素D 1年对老年血压、动脉硬化和心脏功能的影响。

2017年10月,发表在《J Am Heart Assoc》的BEST-D(Biochemical Efficacy and Safety Trial of Vitamin D,维生素D的生化功效和安全性试验)试验,考察了补充维生素D 1年对老年血压、动脉硬化和心脏功能的影响。

背景:维生素D预防血管疾病的相关性尚不确定。BEST-D试验既往报告过维生素D对血清维生素D水平的影响,本报告描述了维生素D对血压、心率、动脉硬化和心脏功能的影响。

方法和结果:本研究为一项随机、双盲、安慰剂对照试验,纳入居住在英国的305例老年人。这些人被分配至每日维生素D 4000 IU(100 μg)、维生素D 2000 IU(50 μg)或安慰剂组。主要结局为25-羟基维生素D血清浓度,次要结局为所有受试者6个月和12个月时的血压、心率和动脉硬化,12个月时的血清N末端脑钠肽前体水平,以及12个月时一个随机筛选亚组(n=177)的心脏功能超声心动图测量。基线平均(SE)血清25羟基维生素D浓度为50(SE 2)nmol/L,12个月后分配至维生素D 4000 IU/d、2000 IU/d或安慰剂的受试者分别增加至137(2.4)、102(2.4)和53(2.4)nmol/L。分配至维生素D组对6个月或12个月时的血压水平、心率或动脉硬化无显着影响,对心脏功能的超声心动图测量或12个月时血清N末端脑钠肽前体水平也没有显着影响。

结果:维生素D对血压、动脉硬化或心脏功能没有任何显着影响,表明维生素D不太可能通过这些机制对心血管疾病有任何获益影响.

原始出处:
Tomson J, Hin H, Emberson J,et al. Effects of Vitamin D on Blood Pressure, Arterial Stiffness, and Cardiac Function in Older People After 1?Year: BEST-D (Biochemical Efficacy and Safety Trial of Vitamin D).J Am Heart Assoc. 2017 Oct 24;6(10). pii: e005707. doi: 10.1161/JAHA.117.005707

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=275732, encodeId=22ed2e573237, content=了解了解.学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Fri Jan 05 13:00:57 CST 2018, time=2018-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356584, encodeId=be3a135658475, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Nov 30 04:29:00 CST 2017, time=2017-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413774, encodeId=fd461413e74e6, content=<a href='/topic/show?id=3a96514459f' target=_blank style='color:#2F92EE;'>#心脏功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51445, encryptionId=3a96514459f, topicName=心脏功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a293020977, createdName=tidiq, createdTime=Thu Nov 30 04:29:00 CST 2017, time=2017-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562753, encodeId=394f1562e53a7, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Thu Nov 30 04:29:00 CST 2017, time=2017-11-30, status=1, ipAttribution=)]
    2018-01-05 1dd8c52fm63(暂无匿称)

    了解了解.学习学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=275732, encodeId=22ed2e573237, content=了解了解.学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Fri Jan 05 13:00:57 CST 2018, time=2018-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356584, encodeId=be3a135658475, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Nov 30 04:29:00 CST 2017, time=2017-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413774, encodeId=fd461413e74e6, content=<a href='/topic/show?id=3a96514459f' target=_blank style='color:#2F92EE;'>#心脏功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51445, encryptionId=3a96514459f, topicName=心脏功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a293020977, createdName=tidiq, createdTime=Thu Nov 30 04:29:00 CST 2017, time=2017-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562753, encodeId=394f1562e53a7, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Thu Nov 30 04:29:00 CST 2017, time=2017-11-30, status=1, ipAttribution=)]
    2017-11-30 zhaojie88
  3. [GetPortalCommentsPageByObjectIdResponse(id=275732, encodeId=22ed2e573237, content=了解了解.学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Fri Jan 05 13:00:57 CST 2018, time=2018-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356584, encodeId=be3a135658475, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Nov 30 04:29:00 CST 2017, time=2017-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413774, encodeId=fd461413e74e6, content=<a href='/topic/show?id=3a96514459f' target=_blank style='color:#2F92EE;'>#心脏功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51445, encryptionId=3a96514459f, topicName=心脏功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a293020977, createdName=tidiq, createdTime=Thu Nov 30 04:29:00 CST 2017, time=2017-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562753, encodeId=394f1562e53a7, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Thu Nov 30 04:29:00 CST 2017, time=2017-11-30, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=275732, encodeId=22ed2e573237, content=了解了解.学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Fri Jan 05 13:00:57 CST 2018, time=2018-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356584, encodeId=be3a135658475, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Nov 30 04:29:00 CST 2017, time=2017-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413774, encodeId=fd461413e74e6, content=<a href='/topic/show?id=3a96514459f' target=_blank style='color:#2F92EE;'>#心脏功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51445, encryptionId=3a96514459f, topicName=心脏功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a293020977, createdName=tidiq, createdTime=Thu Nov 30 04:29:00 CST 2017, time=2017-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562753, encodeId=394f1562e53a7, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Thu Nov 30 04:29:00 CST 2017, time=2017-11-30, status=1, ipAttribution=)]
    2017-11-30 slcumt

相关资讯

Asia Pac Allergy:永久性过敏性鼻炎患者中,血清25-羟甲基维生素D与血嗜酸细胞负相关

维生素D和过敏性鼻炎(AR)之间的关系仍旧不清楚。最近,有研究人员通过在患有AR的病人中检测血清25-羟甲基维生素D(25(OH)D)调水平、血嗜酸细胞和维生素D受体(VDR)在鼻粘膜上的表达调查了它们之间的关系。研究包括了32名患有永久性过敏性鼻炎的病人和25名对照。研究人员通过酶联免疫试验检测了血清25(OH)D的水平,利用自动化的血液系统检测了外周血嗜酸细胞,然而在下鼻甲粘膜中VDR的表达则

J Autoimmun:维持充足的维生素D水平可以帮助预防类风湿性关节炎

伯明翰大学(University of Birmingham)领导的研究发现,维持充足的维生素D水平可能有助于预防风湿性关节炎等炎症疾病的发生。

Lancet Respir Med:维生素D能否降低低基线维生素D水平哮喘患者加重的发生率?

2017年10月,发表在《Lancet Respir Med》上的一项系统评价和Meta分析,研究了补充维生素D 能否降低低基线维生素D水平患者哮喘加重的发生率。研究结果表明:维生素D补充可降低需要全身糖皮质激素治疗的哮喘加重的总体发生率。但未找到明确证据表明,该干预效果在各患者亚组中具有差异。

J Am Heart Assoc:补充维生素D对中心血压参数有何影响?

有报道称,缺乏维生素D的人更有可能患高血压、II型糖尿病以及高血脂。2017年10月,发表在《J Am Heart Assoc》的一项双盲、安慰剂对照亚研究调查了每月、高剂量、长期补充维生素D对中心血压(BP)参数的影响。结果表明,每月高剂量补充维生素D持续1年可降低缺乏维生素D成人的中心BP参数,但不能降低总样本的参数。

JCEM:维生素D对于成人囊性纤维化患者肠道菌群的影响

众多周知肠道菌群紊乱可能会加重囊性纤维化(CF)的严重程度,而维生素D缺乏又是CF患者常见的共发病,可能会影响肠道菌群的组成。近日在JCEM上发表的一篇文章则比较了维生素D充足和不足的CF患者的菌群,并评估了每周高剂量维生素D3的补充方案对于维生素D缺乏(25(OH)D<30ng/ml)的CF患者的肠道和呼吸道微生物的影响。

化学药独霸百亿级骨质疏松药市场,OTC药物占**优势

近几年,我国骨质疏松药物市场呈持续上升趋势,化学药、OTC药物占绝对优势,内资企业在这一市场竞争力相对薄弱。国产药企增长迅猛,未来或将进一步发挥主场优势,而排名前10的产品之间差距并不明显,市场竞争激烈。

Baidu
map
Baidu
map
Baidu
map